| 381 | 0 | 491 |
| 下载次数 | 被引频次 | 阅读次数 |
肺癌是我国发病率和死亡率均位居首位的恶性肿瘤，其中非小细胞肺癌（NSCLC）是肺癌的主要病理类型，约占肺癌总数的80%～85%，包括肺鳞癌、肺腺癌等。表皮生长因子受体（EGFR）突变是NSCLC最常见的驱动因素之一，占亚洲肺腺癌患者的40%～60%。随着精准医学的发展，EGFR酪氨酸激酶抑制剂（EGFR-TKIs）已成为EGFR突变晚期NSCLC患者的标准治疗选择。基于EGFR-TKIs的广泛使用，EGFR-TKIs耐药问题成为临床治疗的主要挑战。针对EGFR-TKIs耐药问题，本专家共识编写组系统检索了2020年1月1日至2025年6月30日PubMed、 Scopus、 Web of Science、 CochraneLibrary、 Embase和Medline数据库中关键词为“Non-small cell lung cancer/NSCLC”“EGFR-TKI”“EGFR mutation”“resistance”等的相关文献及国内外大型学术会议报道共392篇，结合现有循证医学证据，组织专家讨论并制定了EGFR-TKIs耐药后应对策略及标准化质量控制中国专家共识，以期指导临床实践。
Abstract：Lung cancer remains the leading malignancy in China in terms of both incidence and mortality. Among its subtypes, non-small cell lung cancer(NSCLC) accounts for approximately 80% – 85% of all cases, primarily including lung squamous cell carcinoma and lung adenocarcinoma. Epidermal growth factor receptor(EGFR) mutations represent one of the most common oncogenic drivers in NSCLC, occurring in 40% – 60% of Asian patients with lung adenocarcinoma. With the advancement of precision medicine, EGFR-tyrosine kinase inhibitors(EGFR-TKIs) have become a standard first-line treatment for patients with advanced NSCLC harboring EGFR mutations. However, the widespread use of EGFR-TKIs has led to the emergence of drug resistance, which poses a major challenge in clinical management. To address EGFR-TKIs resistance, the expert consensus panel conducted a comprehensive literature review of 392 publications and reports from major academic conferences between January 1, 2020 to June 30, 2025. The search spanned databases including PubMed, Scopus, Web of Science, Cochrane Library, Embase, and Medline using keywords "Non-small cell lung cancer/NSCLC" "EGFR-TKI" "EGFR mutation" and "resistance". Based on the available evidence from evidence-based medicine,the group organized expert discussions and formulated the Chinese Expert Consensus on Strategies and Standardized Quality Control for Managing EGFR-TKIs Resistance in NSCLC, aiming to guide clinical practice.
[1] Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53. DOI:10.1016/j.jncc.2024.01.006.
[2] Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor(EGFR)signaling in cancer[J].Gene, 2006, 366(1):2-16. DOI:10.1016/j.gene. 2005.10.018.
[3] Zhou Q, Zhao H, Lu S, et al. Consensus on the lung cancer management after third-generation EGFR-TKI resistance[J]. Lancet Reg Health West Pac, 2024, 53:101260. DOI:10.1016/j.lanwpc.2024.101260.
[4] Shi Y, Au JSK, Thongprasert S, et al. A prospective,molecular epidemiology study of EGFR mutations in Asian patients with advanced non–small-cell lung cancer of adenocarcinoma histology(PIONEER)[J].J Thorac Oncol, 2014, 9(2):154-162. DOI:10.1097/JTO.0000000000000033.
[5] Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib[J]. N Engl J Med, 2004, 350(21):2129-2139. DOI:10.1056/NEJMoa040938.
[6] Paez JG, J?nne PA, Lee JC, et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J]. Science, 2004, 304(5676):1497-1500.DOI:10.1126/science.1099314.
[7]中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会（CSCO）非小细胞肺癌诊疗指南2024[M].北京：人民卫生出版社，2024:6-192.
[8] National Comprehensive Cancer Network(NCCN). NonSmall Cell Lung Cancer. NCCN; Version 11[EB/OL].[2024-11-25] https：//www. nccn. org/professionals/physician_gls/pdf/nscl.pdf.
[9] Passaro A, J?nne PA, Mok T, et al. Overcoming therapy resistance in EGFR-mutant lung cancer[J]. Nat Cancer,2021, 2(4):377-391. DOI:10.1038/s43018-021-00195-8.
[10]Lu S, Dong X, Jian H, et al. Aeneas:a randomized phaseⅢtrial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non–smallcell lung cancer with EGFR exon 19 deletion or L858R mutations[J]. J Clin Oncol, 2022, 40(27):3162-3171.DOI:10.1200/JCO.21.02641.
[11]Shi Y, Chen G, Wang X, et al. Furmonertinib(AST2818)versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer(FURLONG):a multicentre, double-blind, randomised phase 3 study[J]. Lancet Respir Med, 2022, 10(11):1019-1028. DOI:10.1016/S2213-2600(22)00168-0.
[12]Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer[J]. N Engl J Med, 2018, 378(2):113-125.DOI:10.1056/NEJMoa1713137.
[13]Lu S, Zhou J, Jian H, et al. Befotertinib(D-0316)versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-smallcell lung cancer:a multicentre, open-label, randomised phase 3 study[J]. Lancet Respir Med, 2023, 11(10):905-915. DOI:10.1016/S2213-2600(23)00183-2.
[14]Cho BC, Ahn MJ, Kang JH, et al. Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non–small-cell lung cancer:results from LASER301[J]. J Clin Oncol, 2023, 41(26):4208-4217. DOI:10.1200/JCO.23.00515.
[15]International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, et al.Survival of patients with stageⅠlung cancer detected on CT screening[J]. N Engl J Med, 2006, 355(17):1763-1771. DOI:10.1056/NEJMoa060476.
[16]Ramalingam SS, Vansteenkiste J, Planchard D, et al.Overall survival with osimertinib in untreated, EGFRmutated advanced NSCLC[J]. N Engl J Med, 2020, 382(1):41-50. DOI:10.1056/NEJMoa1913662.
[17]Chen WC, Cheng WC, Chen CL, et al. Assessing EGFRmutated NSCLC with bone metastasis:clinical features and optimal treatment strategy[J]. Cancer Med, 2024, 13(7):e7152. DOI:10.1002/cam4.7152.
[18]Henry DH, Costa L, Goldwasser F, et al. Randomized,double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer(excluding breast and prostate cancer)or multiple nyeloma[J]. J Clin Oncol, 2011, 29(9):1125-1132. DOI:10.1200/JCO.2010.31.3304.
[19]Takeuchi S, Nonaka M, Kadokura M, et al. Prognostic significance of serum squamous cell carcinoma antigen in surgically treated lung cancer[J]. Ann Thorac Cardiovasc Surg, 2003, 9(2):98-104.
[20]Stieber P, Dienemann H, Hasholzner U, et al.Comparison of cytokeratin fragment 19(CYFRA 21-1),tissue polypeptide antigen(TPA)and tissue polypeptide specific antigen(TPS)as tumour markers in lung cancer[J]. Eur J Clin Chem Clin Biochem, 1993, 31(10):689-694. DOI:10.1515/cclm.1993.31.10.689.
[21]王纪文，高佳，赫捷. ProGRP与NSE对小细胞肺癌诊断价值的meta分析[J].中国肺癌杂志，2010,13(12):1094-1100. DOI:10.3779/j.issn.1009-3419.2010.12.03.
[22]Xu J, Liu Z, Bai H, et al. Evaluation of clinical outcomes of icotinib in patients with clinically diagnosed advanced lung cancer with EGFR-sensitizing variants assessed by circulating tumor DNA testing:aphase 2 nonrandomized clinical trial[J]. JAMA Oncol, 2022, 8(9):1328-1332.DOI:10.1001/jamaoncol.2022.2719.
[23]Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors[J]. J Thorac Oncol, 2018, 13(3):323-358.DOI:10.1016/j.jtho.2017.12.001.
[24]Kalemkerian GP, Narula N, Kennedy EB, et al.Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors:American society of clinical oncology endorsement of the college of American pathologists/international association for the study of lung cancer/association for molecular pathology clinical practice guideline update[J]. J Clin Oncol, 2018, 36(9):911-919. DOI:10.1200/JCO.2017.76.7293.
[25]中华医学会病理学分会，国家病理质控中心，中华医学会肿瘤学分会肺癌学组，等.非小细胞肺癌MET临床检测中国专家共识[J].中华病理学杂志，2022,51(11):1094-1103. DOI:10.3760/cma. j. cn112151-20220606-00491.
[26]Lu S, Wang J, Yang N, et al. Savolitinib(Savo)combined with osimertinib(osi)versus chemotherapy(chemo)in EGFR-mutant(EGFRm)and MET-amplification(MET amp)advanced NSCLC after disease progression(PD)on EGFR tyrosine kinase inhibitor(TKI):results from a randomized phase 3SACHI study[J]. J Clin Oncol, 2025, 43(17_suppl).DOI:10.1200/JCO.2025.43.17_suppl.LBA8505.
[27]Zheng Q, Lin X, Qi W, et al. NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer(NSCLC)patients:a prospective,multicenterstudy in China[J]. Lung Cancer, 2024, 194:107897. DOI:10.1016/j.lungcan.2024.107897.
[28]Desai A, Vázquez TA, Arce KM, et al. ctDNA for the evaluation and management of EGFR-mutant non-small cell lung cancer[J]. Cancers, 2024, 16(5):940. DOI:10.3390/cancers16050940.
[29]Liu L, Wang C, Li S, et al. Tumor immune microenvironment in epidermal growth factor receptormutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment:a narrative review[J]. Transl Lung Cancer Res, 2021, 10(9):3823-3839. DOI:10.21037/tlcr-21-572.
[30]Passarelli A, Aieta M, Sgambato A, et al. Targeting immunometabolism mediated by CD73 pathway in EGFRmutated non-small cell lung cancer:anew hope for overcoming immune resistance[J]. Front Immunol,2020, 11:1479. DOI:10.3389/fimmu.2020.01479.
[31]Yang L, He YT, Dong S, et al. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma[J]. J Immunother Cancer, 2022, 10(2):e003534.DOI:10.1136/jitc-2021-003534.
[32]Isomoto K, Haratani K, Hayashi H, et al. Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation–positive non–small cell lung cancer[J]. Clin Cancer Res, 2020, 26(8):2037-2046. DOI:10.1158/1078-0432. CCR-19-2027.
[33]Choudhury NJ, Marra A, Sui JSY, et al. Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers[J]. J Thorac Oncol, 2023,18(4):463-475. DOI:10.1016/j.jtho.2022.11.022.
[34]Liu S, Wu F, Li X, et al. Patients with short PFS to EGFR-TKIs predicted better response to subsequent antiPD-1/PD-L1 based immunotherapy in EGFR common mutation NSCLC[J]. Front Oncol, 2021, 11:639947.DOI:10.3389/fonc.2021.639947.
[35]Yang JJ, Chen HJ, Yan HH, et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer[J].Lung Cancer, 2013, 79(1):33-39. DOI:10.1016/j.lungcan.2012.09.016.
[36]Passaro A, Leighl N, Blackhall F, et al. ESMO expert consensus statements on the management of EGFR mutant non-small-celllung cancer[J]. Ann Oncol, 2022, 33(5):466-487. DOI:10.1016/j.annonc.2022.02.003.
[37]Dingemans AMC, Hendriks LEL, Berghmans T, et al.Definition of synchronous oligometastatic non–small cell lung cancer—aconsensus report[J]. J Thorac Oncol,2019, 14(12):2109-2119. DOI:10.1016/j. jtho. 2019.07.025.
[38]Planchard D, Popat S, Kerr K, et al. Metastatic nonsmall cell lung cancer:ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol,2018, 29:iv192-iv237. DOI:10.1093/annonc/mdy275.
[39]Iyengar P, All S, Berry MF, et al. Treatment of oligometastatic non-small cell lung cancer:an ASTRO/ESTRO clinical practice guideline[J]. Pract Radiat Oncol, 2023, 13(5):393-412. DOI:10.1016/j. prro.2023. 04.004.
[40]Guo T, Ni J, Yang X, et al. Pattern of recurrence analysis in metastatic EGFR-mutant NSCLC treated with osimertinib:implications for consolidative stereotactic body Radiation therapy[J]. Int J Radiat Oncol Biol Phys,2020, 107(1):62-71. DOI:10.1016/j. ijrobp. 2019.12.042.
[41]Dong RF, Zhu ML, Liu MM, et al. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC:from molecular mechanisms to clinical research[J]. Pharmacol Res, 2021, 167:105583. DOI:10.1016/j.phrs.2021.105583.
[42]Li N, Zuo R, He Y, et al. PD-L1 induces autophagy and primary resistance to EGFR–TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway[J]. Cell Death Dis, 2024, 15(8):555. DOI:10.1038/s41419-024-06945-7.
[43]Chmielecki J, Gray JE, Cheng Y, et al. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer[J]. Nat Commun, 2023, 14(1):1070. DOI:10.1038/s41467-023-35961-y.
[44]Ferro A, Marinato GM, Mulargiu C, et al. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced nonsmall cell lung cancer patients:the challenge is open for new therapeutic strategies[J]. Crit Rev Oncol Hematol,2024, 196:104295. DOI:10.1016/j. critrevonc. 2024.104295.
[45]Planchard D, J?nne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC[J]. N Engl J Med, 2023, 389(21):1935-1948. DOI:10.1056/NEJMoa2306434.
[46]Lu S, Hu J, Chen J, et al. Abstract CT053:aumolertinib with or without chemotherapy as first line treatment in locally advanced or metastatic NSCLC with sensitizing EGFR mutations(AENEAS2)[J]. Cancer Res, 2025, 85(8_Suppl_2):CT053-CT053. DOI:10.1158/1538-7445.AM2025-CT053.
[47]Lee CK, Robichaux JP, J?nne PA, et al. 514MO acquired mechanisms of resistance to first-line(1L)osimertinib with or without platinum-based chemotherapy(CT)in EGFR-mutated(EGFRm)advanced NSCLC:preliminary data from FLAURA2[J]. Ann Oncol, 2023,34(suppl_4):S1669-S1670. DOI:10.1016/j. annonc.2023. 10.593.
[48]Wu L , Li B , Fan Y ,et al. 66P:Long-term follow-up of limertinib(ASK120067)in patients with locally advanced or metastatic EGFR T790M NSCLC:a multicentre,single-arm,phaseⅡb study[J]. J Thorac Oncol,2025,20(3):S51-S52. DOI:10.1016/S1556-0864(25)00261-8.
[49]Russo A, Scilla KA, Mehra R, et al. Tracking clonal evolution of EGFR-mutated non-small cell lung cancer through liquid biopsy:management of C797S acquired mutation[J]. Clin Lung Cancer, 2023, 24(7):660-665.DOI:10.1016/j.cllc.2023.07.003.
[50]Wang Y, Yang N, Zhang Y, et al. Effective treatment of lung adenocarcinoma harboring EGFR-activating mutation, T790M, and cis-C797S triple mutations by brigatinib and cetuximab combination therapy[J]. J Thorac Oncol, 2020, 15(8):1369-1375. DOI:10.1016/j.jtho.2020.04.014.
[51]Haura EB, Cho BC, Lee JS, et al. JNJ-61186372(JNJ-372), an EGFR-cMet bispecific antibody, in EGFRdriven advanced non-small cell lung cancer(NSCLC)[J]. J Clin Oncol, 2019, 37(15_suppl):9009. DOI:10.1200/jco.2019.37.15_suppl.9009.
[52]Goldman JW, Horinouchi H, Cho BC, et al. Phase 1/1b study of telisotuzumab vedotin(Teliso-V)+osimertinib(Osi), after failure on prior Osi, in patients with advanced,c-Met overexpressing, EGFR-mutated nonsmall cell lung cancer(NSCLC)[J]. J Clin Oncol, 2022,40(16_suppl):9013. DOI:10.1200/JCO. 2022.40.16_suppl.9013.
[53]Califano R, Passaro A, Tan JL, et al. Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib:outcomes by osimertinib resistance mechanisms in MARIPOSA-2[J]. J Clin Oncol, 2025,43(16_suppl):8639. DOI:10.1200/jco. 2025.43.16_suppl.8639.
[54]中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会（CSCO）小细胞肺癌诊疗指南2024[M].北京：人民卫生出版社，2024:51-72.
[55]Zhang CY, Sun H, Su JW, et al. A potential treatment option for transformed small-cell lung cancer on PD-L1inhibitor-based combination therapy improved survival[J]. Lung Cancer, 2023, 175:68-78. DOI:10.1016/j.lungcan.2022.11.016.
[56]Mok T, Nakagawa K, Park K, et al. Nivolumab plus chemotherapy in epidermal growth factor receptor–mutated metastatic non–small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors:final results of CheckMate 722[J]. J Clin Oncol, 2024, 42(11):1252-1264. DOI:10.1200/JCO.23.01017.
[57]Yang JCH, Lee DH, Lee JS, et al. PhaseⅢKEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant,EGFR–mutant, metastatic nonsquamous non–small cell lung cancer[J]. J Clin Oncol, 2024, 42(34):4029-4039. DOI:10.1200/JCO.23.02747.
[58]Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer(IMpower150):key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised,open-label phase 3 trial[J]. Lancet Respir Med, 2019, 7(5):387-401. DOI:10.1016/S2213-2600(19)30084-0.
[59]Nogami N, Barlesi F, Socinski MA, et al. IMpower150final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain[J]. J Thorac Oncol, 2022, 17(2):309-323.DOI:10.1016/j.jtho.2021.09.014.
[60]Lu S, Wu L, Jian H, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous nonsmall-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitortherapy(ORIENT-31):second interim analysis from a double-blind,randomised, placebo-controlled, phase 3 trial[J]. Lancet Respir Med, 2023, 11(7):624-636. DOI:10.1016/S2213-2600(23)00135-2.
[61]Lu S, Wu L, Jian H, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy(ORIENT-31):first interim results from a randomised, double-blind, multicentre, phase 3 trial[J]. Lancet Oncol, 2022, 23(9):1167-1179. DOI:10.1016/S1470-2045(22)00382-5.
[62]Li Z, Wu L, Jian H, et al. 68P:Survival impact of immunotherapy(IO)after chemo-failure in EGFRmutated NSCLCA post-hoc analysis of the Orient-31 trial[J]. J Thorac Oncol, 2025,20(3_Suppl_1):S52-S53.DOI:10.1016/S1556-0864(25)00263-1.
[63]Zhou C, Dong X, Chen G, et al. OA09.06 IMpower151:phaseⅢstudy of atezolizumab+bevacizumab+chemotherapy in 1L metastatic nonsquamous NSCLC[J].J Thorac Oncol, 2023, 18(Suppl_11):S64-S65. DOI:10.1016/j.jtho.2023.09.059.
[64]Park S, Kim TM, Han JY, et al. PhaseⅢ，randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR-or ALK-rearranged or translocated non–small-cell lung cancer(ATTLAS,KCSG-LU19-04)[J]. J Clin Oncol, 2024,42(11):1241-1251. DOI:10.1200/JCO.23.01891.
[65]Shiraishi Y, Kishimoto J, Sugawara S, et al.Atezolizumab and platinum plus pemetrexed with or without bevacizumab for metastatic nonsquamous non–small cell lung cancer:aphase 3 randomized clinical trial[J]. JAMA Oncol, 2024, 10(3):315. DOI:10.1001/jamaoncol.2023.5258.
[66]Hsu KH, Huang YH, Tseng JS, et al. High PD-L1expression correlates with primary resistance to EGFRTKIs in treatment na?ve advanced EGFR-mutant lung adenocarcinoma patients[J]. Lung Cancer, 2019, 127:37-43. DOI:10.1016/j.lungcan.2018.11.021.
[67]Qin BD, Jiao XD, Yuan LY, et al. Immunotherapybased regimens for patients with EGFR-mutated nonsmall cell lung cancer who progressed on EGFR-TKI therapy[J]. J Immunother Cancer, 2024,12(4):e008818. DOI:10.1136/jitc-2024-008818.
[68]HARMONi-A Study Investigators, Fang W, Zhao Y, et al. Ivonescimab plus chemotherapy in non–small cell lung cancer with EGFR variant:arandomized clinical trial[J]. JAMA, 2024, 332(7):561-570. DOI:10.1001/jama.2024.10613.
[69]Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFRmutant advanced NSCLC after disease progression on osimertinib:primary results from the phaseⅢMARIPOSA-2 study[J]. Ann Oncol, 2024, 35(1):77-90. DOI:10.1016/j.annonc.2023.10.117.
[70]Popat S, Reckamp KL, Califano R, et al. LBA54amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib:second interim overall survival from MARIPOSA-2[J]. Ann Oncol,2024, 35(Suppl_2):S1244-S1245. DOI:10.1016/j.annonc.2024.08.2296.
[71]Leighl NB, Akamatsu H, Lim SM, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor–mutated non–small cell lung cancer:primary results from the phaseⅢPALOMA-3 study[J]. J Clin Oncol, 2024, 42(30):3593-3605. DOI:10.1200/JCO.24.01001.
[72]Soo RA, Popat S, Dellaporta T, et al. 9MO:amivantamab, lazertinib and bevacizumab in EGFRmutant advanced NSCLC with acquired resistance to 3rd generation EGFR-TKI:final results from the phaseⅡETOP AMAZE-lung trial[J]. J Thorac Oncol, 2025, 20(3):S13-S14. DOI:10.1016/S1556-0864(25)00204-7.
[73]Yu HA, Goto Y, Hayashi H, et al. HERTHENAlung01, a phaseⅡtrial of patritumab deruxtecan(HER3-DXd)in epidermal growth factor receptor–mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy[J]. J Clin Oncol, 2023, 41(35):5363-5375. DOI:10.1200/JCO. 23. 01476.
[74]Mok TSK, Yu HA, Lim SM, et al. Patritumab deruxtecan(HER3-DXd)in resistant EGFR-mutated(EGFR m)advanced non-small cell lung cancer(NSCLC)after a third-generation EGFR TKI:the phase 3 HERTHENALung02 study[J]. J Clin Oncol, 2025, 43(16_suppl):8506. DOI:10.1200/JCO.2025.43.16_suppl.8506.
[75]Ahn MJ, Tanaka K, Paz-Ares L, et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non–small cell lung cancer:the randomized, open-label phaseⅢTROPION-Lung01study[J]. J Clin Oncol, 2025, 43(3):260-272. DOI:10.1200/JCO-24-01544.
[76]Ahn MJ, Lisberg A, Goto Y, et al. A pooled analysis of datopotamab deruxtecan in patients with EGFR–mutated NSCLC[J]. J Thorac Oncol, 2025:S1556-0864(25)00761-0. DOI:10.1016/j.jtho.2025.06.002.
[77]U. S. Food and Drug Administration. DATROWAY?（datopotamab deruxtecan-dlnk） for injection, for intravenous use[EB/OL].[2025-06-24] https：//www.accessdata. fda. gov/drugsatfda_docs/label/2025/761464s000lbl.pdf.
[78]Le X, Hendriks L, Morabito A, et al. 1O:Osimertinib(osi)+datopotamab deruxtecan(Dato-DXd)in patients(pts)with EGFR-mutated(EGFRm)advanced NSCLC(aNSCLC)whose disease progressed on first-line(1L)osi:ORCHARD[J]. J Thorac Oncol, 2025, 20(3_Suppl_1):S2-S4. DOI:10.1016/S1556-0864(25)00196-0.
[79]Fang W, Cheng Y, Chen Z, et al. Abstract CT247:updated efficacy and safety of anti-TROP2 ADC SKB264(MK-2870)for previously treated advanced NSCLC in Phase 2 study[J]. Cancer Res, 2024, 84(7_Suppl):CT247-CT247. DOI:10.1158/1538-7445. AM2024-CT247.
[80]Fang W, Li X, Wang Q, et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer:multicentre, open label, randomised controlled trial[J]. BMJ, 2025, 389:e085680. DOI:10.1136/bmj-2025-085680.
[81]Remon J, Besse B, Aix SP, et al. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer(NSCLC):EORTC Lung Cancer Group 1613 APPLE phaseⅡrandomized clinical trial[J]. Ann Oncol, 2023, 34(5):468-476. DOI:10.1016/j.annonc.2023.02.012.
[82]Gray JE, Ahn MJ, Oxnard GR, et al. Early clearance of plasma epidermal growth factor receptor mutations as a predictor of outcome on osimertinib in advanced non–small cell lung cancer; Exploratory analysis from AURA3and FLAURA[J]. Clin Cancer Res, 2023, 29(17):3340-3351. DOI:10.1158/1078-0432.CCR-22-3146.
[83]中国抗癌协会肺癌专业委员会，广东省临床试验协会/中国胸部肿瘤研究协作组.肺癌适应性治疗中国专家共识[J].循证医学，2024,24(4):193-200. DOI:10.12019/j.issn.1671-5144.202407049.
[84]Zhou Q, Xu CR, Cheng Y, et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFRmutated,advanced NSCLC(ARTEMIS-CTONG1509):A multicenter phase 3 study[J]. Cancer Cell, 2021, 39(9):1279-1291.e3. DOI:10.1016/j.ccell.2021.07.005.
[85]Dong S, Wang Z, Zhang JT, et al. Circulating tumor DNA-guided de-escalation targeted therapy for advanced non-small cell lung cancer:anonrandomized controlled trial[J]. JAMA Oncol, 2024,10(7):932. DOI:10.1001/jamaoncol.2024.1779.
[86]Papadimitrakopoulou VA, Mok TS, Han JY, et al.Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor:AURA3 overall survival analysis[J]. Ann Oncol, 2020,31(11):1536-1544. DOI:10.1016/j.annonc.2020.08.2100.
[87]Lu S, Wang Q, Zhang G, et al. Efficacy of aumolertinib(HS-10296)in patients with advanced EGFR T790M+NSCLC:updated post-national medical products administration approval results from the APOLLO registrational trial[J]. J Thorac Oncol, 2022, 17(3):411-422. DOI:10.1016/j.jtho.2021.10.024.
[88]Shi Y, Zhang S, Hu X, et al. Safety, clinical activity,and pharmacokinetics of alflutinib(AST2818)in patients with advanced NSCLC with EGFR T790M mutation[J].J Thorac Oncol, 2020, 15(6):1015-1026. DOI:10.1016/j.jtho.2020.01.010.
[89]Lu S, Zhang Y, Zhang G, et al. Efficacy and safety of befotertinib(D-0316)in patients with EGFR T790Mmutated NSCLC that had progressed after prior EGFR tyrosine kinase inhibitor therapy:aphase 2, multicenter,single-arm, open-label study[J]. J Thorac Oncol, 2022,17(10):1192-1204. DOI:10.1016/j.jtho.2022.06.002.
[90]Shi Y, Li B, Wu L, et al. Efficacy and safety of limertinib(ASK120067)in patients with locally advanced or metastatic EGFR Thr790Met-mutated NSCLC:a multicenter, single-arm, phase 2b study[J]. J Thorac Oncol, 2022, 17(10):1205-1215. DOI:10.1016/j.jtho.2022.05.011.
[91]Xiong A, Ren S, Liu H, et al. Efficacy and safety of SH-1028 in patients with EGFR T790M-Positive NSCLC:amulticenter, single-arm, open-label, phase 2 trial[J].J Thorac Oncol, 2022, 17(10):1216-1226. DOI:10.1016/j.jtho.2022.06.013.
[92]Shi Y, Wu S, Wang K, et al. Efficacy and safety of rezivertinib(BPI-7711)in patients with locally advanced or metastatic/recurrent EGFR T790M-mutated NSCLC:aphase 2b study[J]. J Thorac Oncol, 2022, 17(11):1306-1317. DOI:10.1016/j.jtho.2022.08.015.
[93]Yu HA, Ambrose H, Baik C, et al. 1239P ORCHARD osimertinib+savolitinib interim analysis:a biomarkerdirected phaseⅡplatform study in patients(pts)with advanced non-small cell lung cancer(NSCLC)whose disease has progressed on first-line(1L)osimertinib[J].Ann Oncol, 2021, 32(Suppl_5):S978-S979. DOI:10.1016/j.annonc.2021.08.1844.
[94]Ahn MJ, Kim TM, Bonanno L, et al. 2O:SAVANNAH:savolitinib(savo)+osimertinib(osi)in patients(pts)with EGFRm advanced NSCLC and METoverexpression(OverExp)and/or amplification(Amp)following progressive disease(PD)on osi[J]. J Thorac Oncol,2025, 20(Suppl_3):S4-S5. DOI:10.1016/S1556-0864(25)00197-2.
[95]Tan SW, Kim TM, Guarneri V,et al. Tepotinib+osimertinib for EGFRmutant(EGFRm)NSCLC with MET amplification(METamp)after first-line(1L)osimertinib[J]. J Clin Oncol, 2023, 41(16_suppl):9021. DOI:10.1200/JCO.2023.41.16_suppl.9021.
[96]Rotow J, Patel JD, Hanley MP, et al. Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers[J]. Clin Cancer Res, 2023, 29(16):2979-2987. DOI:10.1158/1078-0432.CCR-22-2189.
[97]Tang X, Hu J, Guo R, et al. RET-AREAL:a multicenter, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs[J]. Cancer Lett, 2025, 612:217455.DOI:10.1016/j.canlet.2025.217455.
[98]Weng CD, Liu KJ, Jin S, et al. Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFRmutated non-small cell lung cancer patients[J]. Transl Lung Cancer Res, 2024, 13(10):2538-2548. DOI:10.21037/tlcr-24-358.
基本信息:
DOI：10.13455/j.cnki.cjcor.113494-20250721-0274
中图分类号:R734.2
引用信息:
[1]王洁,王志杰,徐佳晨,等.EGFR-TKIs耐药后应对策略及标准化质量控制中国专家共识[J].中国肿瘤临床与康复,2025,32(09):547-572.DOI:10.13455/j.cnki.cjcor.113494-20250721-0274.
2025-09-28
2025-09-28